natl health inv - NHI
NHI
Close Chg Chg %
81.75 1.43 1.75%
Closed Market
83.18
+1.43 (1.75%)
Volume: 173.37K
Last Updated:
Apr 2, 2026, 3:59 PM EDT
Company Overview: natl health inv - NHI
NHI Key Data
| Open $82.32 | Day Range 81.66 - 83.37 |
| 52 Week Range 66.41 - 91.38 | Market Cap $4.03B |
| Shares Outstanding 48.46M | Public Float 46.16M |
| Beta 0.66 | Rev. Per Employee N/A |
| P/E Ratio 27.56 | EPS $3.03 |
| Yield 440.12% | Dividend $0.92 |
| EX-DIVIDEND DATE Mar 31, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 325.77K |
NHI Performance
| 1 Week | 1.17% | ||
| 1 Month | -1.73% | ||
| 3 Months | 8.21% | ||
| 1 Year | 16.41% | ||
| 5 Years | 11.10% |
NHI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 89.571 | |
| Number of Ratings | 7 | Current Quarters Estimate | 0.839 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 3.279 | |
| Last Quarter’s Earnings | 0.77 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.02 | Next Fiscal Year Estimate | 3.533 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 4 | 3 |
| Mean Estimate | 0.84 | 0.82 | 3.28 | 3.53 |
| High Estimates | 0.93 | 0.86 | 3.61 | 3.66 |
| Low Estimate | 0.78 | 0.79 | 3.14 | 3.44 |
| Coefficient of Variance | 9.55 | 4.30 | 6.78 | 3.22 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Natl Health Inv - NHI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Natl Health Inv - NHI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 31, 2026 | Kevin C. Pascoe Chief Investment Officer | 73,082 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 31, 2026 | John L. Spaid CFO/EVP Finance | 56,601 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2026 | D. Eric Mendelsohn CEO and President; Director | 137,505 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $73.34 per share | 10,084,616.70 |
| Feb 20, 2026 | D. Eric Mendelsohn CEO and President; Director | 115,450 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $91.02 per share | 10,508,259.00 |
| Feb 20, 2026 | D. Eric Mendelsohn CEO and President; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | James R. Jobe Director | 41,555 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $73.34 per share | 3,047,643.70 |
| Feb 20, 2026 | James R. Jobe Director | 33,497 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $91.02 per share | 3,048,896.94 |
| Feb 20, 2026 | James R. Jobe Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |